Position in PTGX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$3,455,162
+$477,402 QoQ
Shares Held
28,187
-0.2% QoQ
Ownership
0.044%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#114
of 341 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 94%
Shared 0%
None 6%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Pathstone Holdings, LLC holds $101,065,916 across 56 Biotechnology names. PTGX ranks #6 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
45,952 | $22,825,735 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
13,825 | $8,620,440 | |
| 3 | ASND |
Ascendis Pharma A/S
|
20,248 | $5,400,545 | |
| 4 | CYTK |
Cytokinetics Inc
|
47,633 | $4,057,854 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
15,152 | $3,651,176 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
This page
|
28,187 | $3,455,162 | |
| 7 | RPRX |
Royalty Pharma plc
|
54,725 | $3,068,429 | |
| 8 | ARGX |
Argenx SE
|
3,094 | $2,870,519 |
All Filings in PTGX
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,455,162 | 28,187 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $2,977,760 | 28,252 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,435,956 | 16,441 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $887,637 | 13,362 | Shares | Defined | 2025-11-13 | |
| 2025-06-30 | $452,936 | 8,195 | Shares | Defined | 2025-08-12 | |
| No filing history on record for this holder in this stock. | ||||||